Skinvisible's Sunscreen Meets New FDA Guidelines for Broad Spectrum and 80 Minute Water-Resistant Claims
25 Marzo 2014 - 7:05AM
Marketwired
Skinvisible's Sunscreen Meets New FDA Guidelines for Broad Spectrum
and 80 Minute Water-Resistant Claims
Plus Invisicare Patent Supports Eight Hours of Sunscreen
Stabilization
LAS VEGAS, NV--(Marketwired - Mar 25, 2014) - Skinvisible
Pharmaceuticals, Inc. (OTCBB: SKVI) (OTCQB: SKVI) is pleased to
announce that it has successfully completed independent testing to
validate its broad spectrum sunscreen claims according to new
labeling guidelines by the Food and Drug Administration (FDA) which
are designed to help reduce the incidents of skin cancer in the
U.S.
Skinvisible has developed sunscreens using its patented
Invisicare® delivery technology which includes sunscreens with SPF
15, 30 and 50 (the highest SPF allowed by the FDA). The sunscreens
can be labeled with the following claims:
Claim # 1 - Broad-Spectrum: According to the FDA, in order
for a sunscreen to be labeled "broad spectrum" it must prove it
protects against both UVA and UVB rays by having an SPF (Sun
Protection Factor) of at least 15 and a critical wave length of at
least 370 nm. Skinvisible's sunscreen has surpassed both of
these criteria, allowing Skinvisible's broad spectrum sunscreen
label to also state "prevents sunburn, skin cancer and aging due to
the sun".
Claim # 2 - Water-Resistant 80 Minutes: The FDA sunscreen
water resistant claim requires that a sunscreen must have the same
SPF after being in water or sweating for 40 or 80
minutes. Skinvisible's testing was conducted at an independent
laboratory specializing in sunscreen testing. The test
involved human subjects that applied sunscreen to their arm,
followed by the immersion of the arm into a Jacuzzi for 80 minutes
(10 minutes in / 10 minutes out). Skinvisible's sunscreen
successfully completed this testing and is allowed to use
"Water-resistant for 80 Minutes" on its sunscreen label, the
longest length of time allowed by the FDA.
Claim # 3 - Unique Patented Technology / Eight-Hour
Photostability: As previously announced, Skinvisible was granted a
patent from the United States Patent and Trademark Office entitled
"Sunscreen Composition with Enhanced UVA Absorber Stability and
Methods", which provides protection until November
2029. Skinvisible successfully formulated a unique Invisicare®
delivery system specifically for stabilizing avobenzone; the key
sunscreen used in the USA. Data submitted to the US patent
office proved that Skinvisible's sunscreen provides a minimum of
eight hours of photostability.
"The global sun care market is projected to reach $9 billion by
2015, therefore Skinvisible is diligently seeking exclusive
licensees in the US, Canada and globally for our high quality,
exceptional sunscreen formulations," said Terry Howlett, President
and CEO. "Skinvisible has put forth a concerted effort to maximize
the claims for our sunscreens and therefore we can provide
consumers with sun protection which is unsurpassed." He added,
"Our broad spectrum sun care product line, made with either
Avobenzone or Tinosorb-S, along with our moisturizing "after-sun"
products, are fully developed including accelerated stability and
initial production. These products are all formulated with patent
protection and benefits that will resonate with
consumers."
About Skinvisible
Pharmaceuticals, Inc Skinvisible Pharmaceuticals is a
research-and-development company that licenses its proprietary
formulations made with Invisicare, its patented polymer delivery
system that offers life-cycle management and unique enhancements
for topically delivered products. Invisicare holds active
ingredients on the skin for extended periods of time resisting both
wash off and perspiration along with controlling the release of
actives and reducing skin irritation. Skinvisible receives a
combination of license fees, and ongoing royalties for its licensed
product formulations. Skinvisible's value also lies in its ability
to continually generate new IP on topical products formulated with
Invisicare. www.skinvisible.com www.invisicare.com.
Forward-Looking
Statements: This press release contains
'forward looking' statements within the meaning of Section 21A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10k for the quarter ending October 31, 2013).
Contact: Doreen McMorran Phone: 702-433-7154 Email:
info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
